JP2006521286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006521286A5 JP2006521286A5 JP2005501118A JP2005501118A JP2006521286A5 JP 2006521286 A5 JP2006521286 A5 JP 2006521286A5 JP 2005501118 A JP2005501118 A JP 2005501118A JP 2005501118 A JP2005501118 A JP 2005501118A JP 2006521286 A5 JP2006521286 A5 JP 2006521286A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- fusion protein
- fragment
- cea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims 15
- 108020001507 fusion proteins Proteins 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 241001529936 Murinae Species 0.000 claims 5
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 2
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 210000001006 meconium Anatomy 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 101000623904 Homo sapiens Mucin-17 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 102100023125 Mucin-17 Human genes 0.000 claims 1
- 102100034263 Mucin-2 Human genes 0.000 claims 1
- 108010008705 Mucin-2 Proteins 0.000 claims 1
- 102100022693 Mucin-4 Human genes 0.000 claims 1
- 108010008699 Mucin-4 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102000007000 Tenascin Human genes 0.000 claims 1
- 108010008125 Tenascin Proteins 0.000 claims 1
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 claims 1
- 206010054094 Tumour necrosis Diseases 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 101150061829 bre-3 gene Proteins 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical group C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- QCQYVCMYGCHVMR-AAZUGDAUSA-N n-[(2r,3r,4s,5r)-4,5,6-trihydroxy-1-oxo-3-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-yl]acetamide Chemical compound CC(=O)N[C@@H](C=O)[C@H]([C@@H](O)[C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O QCQYVCMYGCHVMR-AAZUGDAUSA-N 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41653102P | 2002-10-08 | 2002-10-08 | |
| US60/416,531 | 2002-10-08 | ||
| PCT/US2002/032307 WO2004032962A1 (en) | 2002-10-08 | 2002-10-11 | Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents |
| USPCT/US02/32307 | 2002-10-11 | ||
| US46716103P | 2003-05-02 | 2003-05-02 | |
| US60/467,161 | 2003-05-02 | ||
| PCT/US2003/031801 WO2004032857A2 (en) | 2002-10-08 | 2003-10-08 | Antibody therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011093352A Division JP5437306B2 (ja) | 2002-10-08 | 2011-04-19 | 抗体療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006521286A JP2006521286A (ja) | 2006-09-21 |
| JP2006521286A5 true JP2006521286A5 (https=) | 2006-11-02 |
| JP4790413B2 JP4790413B2 (ja) | 2011-10-12 |
Family
ID=34830287
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005501118A Expired - Fee Related JP4790413B2 (ja) | 2002-10-08 | 2003-10-08 | 抗体療法 |
| JP2011093352A Expired - Fee Related JP5437306B2 (ja) | 2002-10-08 | 2011-04-19 | 抗体療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011093352A Expired - Fee Related JP5437306B2 (ja) | 2002-10-08 | 2011-04-19 | 抗体療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (8) | US7803372B2 (https=) |
| EP (1) | EP1572131B1 (https=) |
| JP (2) | JP4790413B2 (https=) |
| KR (1) | KR20050065587A (https=) |
| CN (1) | CN101972478B (https=) |
| AU (1) | AU2003282752A1 (https=) |
| CA (1) | CA2501616C (https=) |
| IL (3) | IL167901A (https=) |
| WO (1) | WO2004032857A2 (https=) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| CN101972478B (zh) * | 2002-10-08 | 2012-10-31 | 免疫医疗公司 | 抗体治疗 |
| EP1746157A4 (en) * | 2004-04-27 | 2009-02-18 | Chugai Pharmaceutical Co Ltd | PROCESS FOR PLASMA CELL PROGRAMMING |
| BRPI0511187A (pt) * | 2004-05-20 | 2007-12-04 | Zymogenetics Inc | método para tratar cáncer em um indivìduo |
| WO2006084075A2 (en) * | 2005-02-02 | 2006-08-10 | Raven Biotechnologies, Inc. | Adam-9 modulators |
| US7601355B2 (en) * | 2005-06-01 | 2009-10-13 | Northwestern University | Compositions and methods for altering immune function |
| RU2423381C2 (ru) | 2005-07-25 | 2011-07-10 | Трабьон Фармасьютикалз, Инк. | Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул |
| WO2007111714A2 (en) | 2005-11-28 | 2007-10-04 | Zymogenetics, Inc. | Il-21 antagonists |
| US20090226444A1 (en) | 2005-12-21 | 2009-09-10 | Micromet Ag | Pharmaceutical antibody compositions with resistance to soluble cea |
| NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| DK2164514T3 (en) | 2007-05-21 | 2017-02-27 | Alderbio Holdings Llc | Antibodies to IL-6 and its use |
| US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| DK3281952T3 (da) * | 2007-10-30 | 2020-08-03 | Philogen Spa | Antigen, der er forbundet med reumatoid artritis |
| US7883700B2 (en) | 2007-12-07 | 2011-02-08 | Zymogenetics, Inc. | Anti-human IL-21 monoclonal antibodies |
| KR101658247B1 (ko) | 2008-01-03 | 2016-09-22 | 더 스크립스 리서치 인스티튜트 | 모듈 인식 도메인을 통한 항체 표적화 |
| US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
| US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
| RU2531754C2 (ru) | 2008-04-11 | 2014-10-27 | ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US | Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| KR20180077322A (ko) | 2009-04-30 | 2018-07-06 | 텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드． | 항-ｃｅａｃａｍ1 항체들과 이를 이용하는 방법들 |
| SG177613A1 (en) | 2009-07-10 | 2012-03-29 | Linzy O Scott Iii | Methods and compositions for treating thyroid-related medical conditions with reduced folates |
| EP2478110B1 (en) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| CN102740888B (zh) | 2009-11-24 | 2016-10-12 | 奥尔德生物制药公司 | Il-6抗体及其用途 |
| ES2978177T3 (es) | 2009-12-02 | 2024-09-06 | Immunomedics Inc | Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer |
| WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
| CA2818813C (en) | 2010-11-23 | 2020-10-06 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of oral mucositis |
| CN102153655B (zh) * | 2010-12-29 | 2013-06-26 | 吉林大学 | 一种靶向抗肿瘤重组蛋白质及其制备方法 |
| EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| ES2743423T3 (es) | 2012-10-03 | 2020-02-19 | Philogen Spa | Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal |
| MX338711B (es) | 2012-10-12 | 2016-04-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| WO2015012904A2 (en) * | 2012-12-13 | 2015-01-29 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| CN107753954A (zh) * | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量 |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| EP2774930A1 (en) | 2013-03-07 | 2014-09-10 | Aptenia S.R.L. | Metallocene compounds and labeled molecules comprising the same for in vivo imaging. |
| MX362970B (es) | 2013-03-13 | 2019-02-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| JP6493692B2 (ja) | 2013-03-15 | 2019-04-10 | セルジーン コーポレイション | 修飾されたｔリンパ球 |
| US10150800B2 (en) | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
| CA2924398A1 (en) * | 2013-11-05 | 2015-05-14 | Immunomedics, Inc. | Humanized anti-ceacam5 antibody and uses thereof |
| US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
| US10550196B2 (en) | 2014-04-27 | 2020-02-04 | Famewave Ltd. | Humanized antibodies against CEACAM1 |
| EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| KR101783907B1 (ko) | 2016-03-15 | 2017-10-10 | 다이노나(주) | ＣＤ66ｃ에 대한 항체와 화학치료제를 포함하는 폐암 예방 또는 치료용 약학조성물 |
| AU2017257254B2 (en) | 2016-04-27 | 2022-02-24 | Immunomedics, Inc. | Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
| EP3525829A1 (en) | 2016-10-11 | 2019-08-21 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| JP7100028B2 (ja) | 2016-10-20 | 2022-07-12 | セルジーン コーポレイション | セレブロン系のヘテロ二量体化可能なキメラ抗原受容体 |
| EP3600283A4 (en) | 2017-03-27 | 2020-12-16 | Immunomedics, Inc. | TREATMENT OF TROP-2 EXPRESSIVE TRIPLE NEGATIVE BREAST CANCER WITH SACITUZUMAB GOVITECAN AND A RAD51 INHIBITOR |
| US10799597B2 (en) | 2017-04-03 | 2020-10-13 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| EP4426727A2 (en) | 2021-11-03 | 2024-09-11 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| KR20250024741A (ko) | 2022-03-23 | 2025-02-19 | 시나픽스 비.브이. | 암배아성 항원을 발현하는 종양을 표적화하기 위한 항체-컨쥬게이트 |
| CN115344997B (zh) * | 2022-07-11 | 2024-05-31 | 中国水利水电科学研究院 | 夏玉米植株叶片-冠层-像元尺度氮浓度协同预测方法 |
| US12521446B2 (en) | 2024-02-27 | 2026-01-13 | Bristol-Myers Squibb Company | Anti-CEACAM5 antibody drug conjugates |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4818709A (en) * | 1983-01-21 | 1989-04-04 | Primus Frederick J | CEA-family antigens, Anti-CEA antibodies and CEA immunoassay |
| US4970071A (en) | 1985-01-18 | 1990-11-13 | Mcmichael John | Immunotherapeutic methods and compositions employing antigens characteristic of non human malignant neoplasms |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP0302435A1 (en) * | 1987-07-31 | 1989-02-08 | Neorx Corporation | Method for augmenting antibody-dependent cellular cytotoxicity |
| GB8800078D0 (en) | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel antibodies |
| US5843708A (en) * | 1988-01-05 | 1998-12-01 | Ciba-Geigy Corporation | Chimeric antibodies |
| AU625613B2 (en) | 1988-01-05 | 1992-07-16 | Novartis Ag | Novel chimeric antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5081235A (en) * | 1989-07-26 | 1992-01-14 | City Of Hope | Chimeric anti-cea antibody |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US6096289A (en) * | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
| US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5443953A (en) | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
| US6811779B2 (en) * | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
| US5798100A (en) | 1994-07-06 | 1998-08-25 | Immunomedics, Inc. | Multi-stage cascade boosting vaccine |
| IL115177A0 (en) | 1994-09-16 | 1995-12-31 | Immunomedics Inc | Phosphorus-32 labeling of antibodies for cancer therapy |
| US5874540A (en) * | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| US7011812B1 (en) * | 1996-05-03 | 2006-03-14 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
| EP0954340B1 (en) * | 1996-05-03 | 2007-06-27 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer |
| KR20060079258A (ko) * | 1996-10-18 | 2006-07-05 | 제넨테크, 인크. | 항-ＥｒｂＢ２ 항체 |
| US7074405B1 (en) * | 1998-06-22 | 2006-07-11 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| JP2002525268A (ja) * | 1998-09-16 | 2002-08-13 | オンコファーマシューティカル， インコーポレイテッド | ゴルジ装置妨害剤の注射可能な処方物での腫瘍学的腫瘍の処置 |
| ATE330972T1 (de) * | 1999-06-09 | 2006-07-15 | Genentech Inc | Apo-2l rezeptor-agonist und cpt-11 synergie- effekt |
| CN100340575C (zh) * | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
| US7906492B2 (en) * | 2001-01-16 | 2011-03-15 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| US20040043030A1 (en) * | 2001-07-31 | 2004-03-04 | Immunomedics, Inc. | Polymeric delivery systems |
| CA2478047C (en) * | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| KR20040101428A (ko) * | 2002-04-09 | 2004-12-02 | 메르크 파텐트 게엠베하 | 항유전인자형 항-ｃｅａ 항체 분자 및 암백신으로서의이의 용도 |
| CN101972478B (zh) * | 2002-10-08 | 2012-10-31 | 免疫医疗公司 | 抗体治疗 |
| KR20050073488A (ko) * | 2002-10-08 | 2005-07-13 | 이뮤노메딕스, 인코오포레이티드 | Ⅲ종 항-ｃｅａ 단클론 항체들 및 치료제들을 이용한 조합치료법 |
| US7727725B2 (en) * | 2006-04-27 | 2010-06-01 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof |
| EP2478110B1 (en) * | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
-
2003
- 2003-10-08 CN CN2010105006839A patent/CN101972478B/zh not_active Expired - Fee Related
- 2003-10-08 CA CA2501616A patent/CA2501616C/en not_active Expired - Fee Related
- 2003-10-08 KR KR1020057006187A patent/KR20050065587A/ko not_active Withdrawn
- 2003-10-08 WO PCT/US2003/031801 patent/WO2004032857A2/en not_active Ceased
- 2003-10-08 US US10/680,734 patent/US7803372B2/en not_active Expired - Fee Related
- 2003-10-08 JP JP2005501118A patent/JP4790413B2/ja not_active Expired - Fee Related
- 2003-10-08 AU AU2003282752A patent/AU2003282752A1/en not_active Abandoned
- 2003-10-08 EP EP03774636.9A patent/EP1572131B1/en not_active Expired - Lifetime
-
2005
- 2005-04-07 IL IL167901A patent/IL167901A/en active IP Right Grant
-
2007
- 2007-05-01 US US11/742,725 patent/US20070202044A1/en not_active Abandoned
- 2007-10-31 US US11/932,530 patent/US7662378B2/en not_active Expired - Fee Related
-
2009
- 2009-12-16 US US12/639,298 patent/US7919090B2/en not_active Expired - Fee Related
-
2011
- 2011-02-18 US US13/030,204 patent/US8062636B2/en not_active Expired - Fee Related
- 2011-04-19 JP JP2011093352A patent/JP5437306B2/ja not_active Expired - Fee Related
- 2011-09-26 US US13/245,330 patent/US8216572B2/en not_active Expired - Fee Related
-
2012
- 2012-05-21 US US13/476,157 patent/US8535676B2/en not_active Expired - Fee Related
- 2012-08-16 IL IL221508A patent/IL221508A/en active IP Right Grant
- 2012-08-16 IL IL221507A patent/IL221507A/en active IP Right Grant
-
2013
- 2013-08-15 US US13/967,845 patent/US8778342B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006521286A5 (https=) | ||
| CN101972478B (zh) | 抗体治疗 | |
| JP2021501162A5 (https=) | ||
| CN100548374C (zh) | 用ⅲ类抗cea单克隆抗体和治疗剂进行联合治疗 | |
| JP2023511595A5 (https=) | ||
| KR20200020902A (ko) | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 | |
| CA2478047A1 (en) | Rs7 antibodies | |
| RS61668B1 (sr) | Lečenje multiplog mijeloma (mm) | |
| JP2023536631A5 (https=) | ||
| CN114450025A (zh) | 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症 | |
| JP2022521773A5 (https=) | ||
| CN121548431A (zh) | 包含偶联物的药物组合的治疗方法和用途 | |
| WO2024183643A1 (zh) | 含抗tim-3抗体的药物组合 | |
| JP2023550462A5 (https=) | ||
| US20250345449A1 (en) | Anti-cd123 immunoconjugates for the treatment of blastic plasmacytoid cell neoplasm | |
| WO2024199343A1 (zh) | 抗trop2抗体联合靶向trop2的药物治疗癌症的用途 | |
| WO2025167929A1 (zh) | 抗体药物偶联物和雄激素受体拮抗剂的联合应用 | |
| TW202602488A (zh) | 治療ｄｌｌ３陽性癌症受試者中腦轉移之方法 | |
| RU2025101350A (ru) | Дозирование для лечения биспецифическими антителами к fcrh5/cd3 | |
| HK1139316B (en) | Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents | |
| HK1139316A (en) | Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents |